Risk for Parkinson’s disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET A. LaihinenH. RuottinenU. K. Rinne Pages: 110 - 113
Cognition and emotion in different stages and subtypes of Parkinson’s disease F. StocchiL. Brusa Pages: 114 - 121
Thalamic, pallidal, or subthalamic surgery for Parkinson’s disease? P. KrackM. PoeppingG. Deuschl Pages: 122 - 134
Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease D. J. Brooks Pages: II11 - II18
Mitochondrial dysfunction – a pathogenetic factor in Parkinson’s disease H. ReichmannB. Janetzky Pages: II63 - II68
Projections from basal ganglia to tegmentum: a subcortical route for explaining the pathophysiology of Parkinson’s disease signs? P. J. DelwaideJ.-L. PepinA. M. de Noordhout Pages: II75 - II81
Genetic influence on the development of Parkinson’s disease O. RiessW. KuhnR. Krüger Pages: II69 - II74
MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies E. GrünblattS. MandelM. B. H. Youdim Pages: II95 - II102
Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson’s disease A. PlaitakisP. Shashidharan Pages: II25 - II35
The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson’s disease Olivier Rascol Pages: II51 - II57
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms T. N. ChaseJ. D. OhS. Konitsiotis Pages: II36 - II42
Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments Peter Jenner Pages: II43 - II50
Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson’s disease P. FoleyP. Riederer Pages: II82 - II94
